WEST COLUMBIA, S.C., Oct. 24, 2023 /PRNewswire/ -- Nephron Pharmaceuticals Corporation today announced the new hiring of six key executives.
Nephron Pharmaceuticals and Canton Biologics recently announced capital raises totaling hundreds of millions of dollars, joining the growing market for contract and development manufacturing companies.
WEST COLUMBIA, S.C., Aug. 8, 2023 /PRNewswire/ -- Nephron 503B Outsourcing Facility, a division of Nephron Pharmaceuticals Corporation, is focused on resolving drug shortage concerns with the production of 0.5% Albuterol 5 mL, del Nido Cardioplegia, Lidocaine 1% and Succinylcholine products.
WEST COLUMBIA, S.C., June 8, 2023 /PRNewswire/ -- Nephron Pharmaceuticals Corporation today announced Christopher Fortier, PharmD, FASHP, CPEL, will join as President of its 503B Outsourcing Facility.
WEST COLUMBIA, S.C., May 31, 2023 /PRNewswire/ -- Nephron Pharmaceuticals Corporation today announced that preservative-free 0.5% Albuterol Sulfate Inhalation Solution is available now in a 25 mg/5 mL pre-filled vial.
Akorn, the “sole manufacturer” of a certain dose of liquid albuterol, has stopped production, FDA tweeted Wednesday. Two weeks ago, Akorn filed for bankruptcy and mothballed its U.S. operations. The closure swept up facilities like Akorn’s Decatur, Illinois, manufacturing plant, which was licensed to make the specific form of the drug in shortage.
Enforcement Report - Week of March 8, 2023
Enforcement Report - Week of February 1, 2023
Nephron Pharmaceuticals Corporation on Health Canada Inspection List